Having trouble accessing articles? Reset your cache.

NICE backs thalidomide, Velcade for MM

The U.K.'s NICE issued a final appraisal determination (FAD) covering the use of thalidomide from Celgene Corp. (NASDAQ:CELG)

Read the full 187 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE